Table 1 Demographic and clinicopathological manifestations
Variables | All (n = 68) |
|---|---|
Gender, n (%) | |
Male | 40 (58.8%) |
Female | 28 (41.2%) |
Age (yr, mean ± SD) | 57.8 ± 14.2 |
ECOG score, n (%) | |
0 | 10 (14.7%) |
1 | 46 (67.6%) |
2 | 11 (16.2%) |
3 | 1 (1.5%) |
4 | 0 |
5 | 0 |
Primary tumor site, n (%) | |
Rectum | 47 (69.1%) |
Sigmoid colon | 6 (8.8%) |
Descending colon | 1 (1.5%) |
Transverse colon | 2 (2.9%) |
Cecum and ascending colon | 12 (17.6%) |
Grade | |
G1 | 5 (7.4%) |
G2 | 15 (22.1%) |
G3 | 48 (70.6%) |
Differentiation | |
NET | 27 (39.7%) |
NEC | 41 (60.3%) |
Synaptophysin, n (%) | |
Positive | 61 (94.1%) |
Negative | 1 (1.5%) |
Unknown | 3 (4.4%) |
Chromogranin, n (%) | |
Positive | 39 (57.4%) |
Negative | 23 (33.8%) |
Unknown | 6 (8.8%) |
CD56, n (%) | |
Positive | 50 (73.5%) |
Negative | 6 (8.8%) |
Unknown | 12 (17.6%) |
Ki67 [median (range)] | 50% (1%, 95%) |
Clinical T stage, n (%) | |
T1, T2 | 6 (8.8%) |
T3, T4 | 62 (91.2%) |
Clinical N stage, n (%) | |
N0 | 8 (11.8%) |
N1 | 60 (90.2%) |
Site of metastasis, n (%) | |
Liver | 54 (79.4%) |
Lung | 2 (2.9%) |
Bone | 12 (17.6%) |
Distant lymph nodes | 16 (23.5%) |
Peritoneum | 5 (7.4%) |
Others | 3 (4.4%) |
Treatment strategy | |
PTR + chemotherapy | 13 (19.1%) |
Chemotherapy + PTR | 4 (5.9%) |
Chemotherapy + PTR + chemotherapy | 6 (8.8%) |
Chemotherapy alone | 32 (47.1%) |
PTR alone | 9 (13.2%) |
No treatment | 4 (5.9%) |
Operation methods, n (%) | |
Dixon | 12 (17.6%) |
Miles | 3 (4.4%) |
Hartmann | 1 (1.5%) |
Sigmoidectomy | 5 (7.4%) |
Right hemicolectomy | 11 (16.2%)6 |
Only colostomy | 5 (7.4%) |
Only stent placement | 1 (1.5%) |
First-line chemotherapy regimen | |
Fluorouracil-based regimens | 22 (32.3%) |
Platinum-based regimens | 27 (39.7%) |
Anlotinib | 3 (4.4%) |
No chemotherapy | 13 (11.8%) |
Unknown | 5 (11.8%) |
Cycles of chemotherapy [median (range)] | 5 (0, 42) |